PHGE BiomX Inc. Stock Quote

PHGE [AMEX]

Healthcare | Drug Manufacturers - Specialty & Generic | Israel

Index	-	P/E	-	EPS (ttm)	-1.42	Insider Own	2.40%	Shs Outstand	27.08M	Perf Week	1.27%
Market Cap	47.21M	Forward P/E	-	EPS next Y	-	Insider Trans	9.61%	Shs Float	22.84M	Perf Month	-1.85%
Income	-34.90M	PEG	-	EPS next Q	-	Inst Own	24.40%	Short Float	0.13%	Perf Quarter	-34.57%
Sales	-	P/S	-	EPS this Y	64.40%	Inst Trans	-	Short Ratio	0.33	Perf Half Y	-65.44%
Book/sh	1.97	P/B	0.81	EPS next Y	-	ROA	-49.70%	Target Price	12.50	Perf Year	-76.30%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-65.40%	52W Range	1.42 - 9.05	Perf YTD	-0.62%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-82.43%	Beta	-
Dividend %	-	Quick Ratio	7.80	Sales past 5Y	-	Gross Margin	-	52W Low	11.97%	ATR	0.15
Employees	95	Current Ratio	7.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	44.70	Volatility	11.70% 8.62%
Optionable	No	Debt/Eq	0.27	EPS Q/Q	2.90%	Profit Margin	-	Rel Volume	0.43	Prev Close	1.65
Shortable	Yes	LT Debt/Eq	0.27	Earnings	Nov 15 BMO	Payout	-	Avg Volume	92.85K	Price	1.59
Recom	-	SMA20	1.39%	SMA50	-13.17%	SMA200	-60.05%	Volume	39,962	Change	-3.64%

Apr-15-21

Initiated

Ladenburg Thalmann

Buy

$25

Jan-04-22 07:00AM	BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation Business Wire
Nov-17-21 08:00AM	BiomX Presenting at Two Upcoming Conferences in November GlobeNewswire
Nov-15-21 06:00AM	BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Nov-09-21 08:00AM	BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021 GlobeNewswire
Oct-25-21 10:00AM	Down 28.1% in 4 Weeks, Here's Why BiomX Inc. (PHGE) Looks Ripe for a Turnaround Zacks
Oct-18-21 07:00AM	BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study GlobeNewswire -12.35%
Oct-13-21 07:00AM	BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005 GlobeNewswire -5.15%
Sep-02-21 04:05PM	BiomX to Present at Upcoming September Investor Conferences GlobeNewswire -7.29%
Aug-16-21 06:30AM	BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire -7.65%
Aug-12-21 08:00AM	BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021 GlobeNewswire
Jul-26-21 08:13AM	BiomX Inc. Announces $15 Million Registered Direct Offering GlobeNewswire +9.45%
Jun-14-21 06:30AM	BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages Business Wire
Jun-09-21 06:30AM	BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference Business Wire
May-25-21 10:46AM	BiomX Reports Q1 Earnings; Shares Jump 6% SmarterAnalyst
May-24-21 06:30AM	BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates Business Wire
06:15AM	BiomX Inc to Host Earnings Call ACCESSWIRE
May-18-21 08:00AM	BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease GlobeNewswire
06:30AM	BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021 Business Wire
Apr-20-21 07:00AM	BiomX to Present at Upcoming April Investor Events Business Wire
Mar-31-21 06:30AM	BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Business Wire
05:45AM	BiomX Inc to Host Earnings Call ACCESSWIRE
Mar-24-21 06:30AM	BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021 Business Wire
Mar-02-21 07:00AM	BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin Business Wire +10.77%
Mar-01-21 07:00AM	BiomX to Present at Upcoming March Investor Conferences Business Wire +7.29%
Feb-02-21 06:30AM	BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy Business Wire
Jan-04-21 06:30AM	BiomX to Present at Upcoming January Investor Conferences Business Wire
Dec-09-20 04:30PM	BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer Business Wire
Dec-02-20 06:21PM	Here is What Hedge Funds Think About BiomX Inc. (PHGE) Insider Monkey -5.06%
Nov-16-20 06:30AM	BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease Business Wire
Nov-12-20 06:30AM	BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates Business Wire
06:15AM	BiomX Inc to Host Earnings Call ACCESSWIRE
Nov-10-20 04:30PM	BiomX to Present at Upcoming November Investor Conferences Business Wire
Nov-05-20 06:30AM	BiomX to Report Third Quarter 2020 Financial Results on Nov. 12, 2020 Business Wire
Nov-04-20 06:30AM	BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease Business Wire
Oct-21-20 06:30AM	BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the Infectious Disease Society of America (IDSA) IDWeek Conference 2020 Business Wire
Oct-05-20 06:30AM	BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors Business Wire
Sep-10-20 04:30PM	BiomX to Present at Upcoming September Investor Conferences Business Wire
Sep-02-20 06:30AM	BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease Business Wire
Aug-13-20 06:30AM	BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire -16.42%
Aug-12-20 12:17PM	Is BiomX Inc. (NYSEMKT:PHGE) Popular Amongst Institutions? Simply Wall St. -7.75%
Aug-06-20 07:00AM	BiomX to Report Second Quarter 2020 Financial Results on Aug. 13, 2020 Business Wire
May-14-20 06:30AM	BiomX Reports First Quarter 2020 Financial Results and Provides Business Update Business Wire -8.48%
May-11-20 05:00PM	BiomX to Announce First Quarter 2020 Financial Results on May 14, 2020 Business Wire
Apr-07-20 04:05PM	BiomX Announces Date of 2020 Annual Meeting of Stockholders Business Wire -11.28%
Mar-31-20 06:30AM	BiomX Announces Positive Topline Data from Phase 1 Study for Lead Candidate BX001 for Acne-Prone Skin Business Wire -9.33%
Mar-26-20 06:30AM	BiomX Reports Full Year 2019 Financial Results and Provides Business Update Business Wire +7.45%
Mar-20-20 08:00AM	BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting Business Wire
Feb-17-20 07:00AM	BiomX To Present Pre-clinical Data at the Plenary Session of the AACR Microbiome, Viruses, and Cancer Conference Business Wire
Dec-02-19 07:30AM	BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin Business Wire
Nov-12-19 07:30AM	BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis Business Wire -5.53%
07:25AM	Stone Street Group Initiates Coverage On BiomX Inc. PR Newswire
Nov-04-19 05:38PM	BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director Business Wire
07:30AM	BiomX To Present at Plenary Session of the AASLD Liver Conference Business Wire

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wolfson Marina	SVP of Finance & Operations	Jul 28	Buy	4.00	3,750	15,000	3,750	Jul 30 09:55 AM
Sullivan Lynne Marie	Director	Jul 28	Buy	4.00	12,500	50,000	12,500	Jul 30 09:53 AM
Solomon Jonathan Eitan	Chief Executive Officer	Jul 28	Buy	4.00	25,000	100,000	25,000	Jul 30 09:52 AM
Greig Russell	Director	Jul 28	Buy	4.00	3,750	15,000	3,750	Jul 30 09:50 AM
SEKHRI PAUL J	Director	Jul 28	Buy	4.00	12,500	50,000	12,500	Jul 30 09:49 AM
Moses Alan Charles	Director	Jul 28	Buy	4.00	5,000	20,000	5,000	Jul 30 09:48 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience